18 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
10 Jun 24
Other Events
6:05am
participants with quantifiable levels at baseline and day 14 are included in the figures. *% of healthy volunteer FXN level is calculated by dividing … each participant's FXN level by the average FXN level (16.34 pg/µg) from the noninterventional healthy volunteer study (N=60). 25 mg of Nomlabofusp 50
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
50% of the average healthy volunteer level.
The long-term safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
volunteer FXN level is calculated by dividing each participant's FXN level by the average FXN level (16.34 pg/µg) from the noninterventional healthy … volunteer study (N=60). 25 mg of Nomlabofusp 50 mg of Nomlabofusp Baseline FXN levels as a % of average FXN level in healthy volunteers FXN levels
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
days of Daily Nomlabofusp Only participants with quantifiable levels at baseline and day 14 are included in the figures. *% of healthy volunteer FXN … level is calculated by dividing each participant's FXN level by the average FXN level (16.34 pg/µg) from the noninterventional healthy volunteer study (N
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
level observed in healthy volunteers, with 3 patients achieving levels greater than 50% of the average healthy volunteer level.
In February 2024, Larimar
8-K
EX-99.1
utmym
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
EX-99.2
5d3ymwtrk3o3b34
11 Mar 24
Other Events
4:09pm
8-K
EX-99.3
qemo9b9l2 hp92
11 Mar 24
Other Events
4:09pm
424B5
w1b 0ruw3
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
r0d4nd w5gf7lhmws
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.3
6jfmom8n
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
c7o5u8 e8ori97p
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
1t6iazcm
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
stmlcvn
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am
8-K
EX-99.1
jas4i4w9ysh1
12 Nov 21
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
7:21am
8-K
EX-99.1
bj1b30ru0ih
12 Aug 21
Larimar Therapeutics Reports Second Quarter 2021 Operating and Financial Results
10:29am
- Prev
- 1
- Next